keyword
MENU ▼
Read by QxMD icon Read
search

neda AND "multiple sclerosis"

keyword
https://www.readbyqxmd.com/read/30116299/long-term-evaluation-of-neda-3-status-in-relapsing-remitting-multiple-sclerosis-patients-after-switching-from-natalizumab-to-fingolimod
#1
Lara Diem, Krassen Nedeltchev, Timo Kahles, Lutz Achtnichts, Oliver Findling
Background: Natalizumab significantly reduces the disease activity in patients with relapsing-remitting multiple sclerosis but due to the risk of progressive multifocal leukoencephalopathy it is often discontinued. Fingolimod is seen as an alternative, but there are no long-term analyses of the efficacy of fingolimod in this setting using the no evidence of disease activity (NEDA)-3 criteria. We provide an assessment of patients who discontinued natalizumab and switched to fingolimod or other treatments by evaluating the proportion of patients who fulfil NEDA-3 criteria after prolonged follow-up periods...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/30102815/no-evidence-of-disease-activity-in-people-with-multiple-sclerosis-neda-in-pwms
#2
Monica Marta
The advances in the management of people with multiple sclerosis (pwMS) in past 12 years have been incomparable. It is now possible to prevent the relentless course of active MS much better and aim at better outcomes for our patients. Are better outcomes achieved with "no evidence of disease activity" or NEDA? What is NEDA and does it matter?. This article is protected by copyright. All rights reserved.
August 13, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/30090102/immunophenotype-and-transcriptome-profile-of-patients-with-multiple-sclerosis-treated-with-fingolimod-setting-up-a-model-for-prediction-of-response-in-a-2-year-translational-study
#3
Irene Moreno-Torres, Coral González-García, Marco Marconi, Aranzazu García-Grande, Luis Rodríguez-Esparragoza, Víctor Elvira, Elvira Ramil, Lucía Campos-Ruíz, Ruth García-Hernández, Fátima Al-Shahrour, Coral Fustero-Torre, Alicia Sánchez-Sanz, Antonio García-Merino, Antonio José Sánchez López
Background: Fingolimod is a functional sphingosine-1-phosphate antagonist approved for the treatment of multiple sclerosis (MS). Fingolimod affects lymphocyte subpopulations and regulates gene expression in the lymphocyte transcriptome. Translational studies are necessary to identify cellular and molecular biomarkers that might be used to predict the clinical response to the drug. In MS patients, we aimed to clarify the differential effects of fingolimod on T, B, and natural killer (NK) cell subsets and to identify differentially expressed genes in responders and non-responders (NRs) to treatment...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30021640/neurofilament-levels-disease-activity-and-brain-volume-during-follow-up-in-multiple-sclerosis
#4
Irene Håkansson, Anders Tisell, Petra Cassel, Kaj Blennow, Henrik Zetterberg, Peter Lundberg, Charlotte Dahle, Magnus Vrethem, Jan Ernerudh
BACKGROUND: There is a need for clinically useful biomarkers of disease activity in clinically isolated syndrome (CIS) and relapsing remitting MS (RRMS). The aim of this study was to assess the correlation between neurofilament light chain (NFL) in cerebrospinal fluid (CSF) and serum and the relationship between NFL and other biomarkers, subsequent disease activity, and brain volume loss in CIS and RRMS. METHODS: A panel of neurodegenerative and neuroinflammatory markers were analyzed in repeated CSF samples from 41 patients with CIS or RRMS in a prospective longitudinal cohort study and from 22 healthy controls...
July 18, 2018: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29974307/brain-volume-loss-is-present-in-japanese-multiple-sclerosis-patients-with-no-evidence-of-disease-activity
#5
Hiroaki Yokote, Tomoyuki Kamata, Shuta Toru, Nobuo Sanjo, Takanori Yokota
No evidence of disease activity-3 (NEDA-3), defined as absence of clinical relapse, disability progression, and brain magnetic resonance imaging (MRI) activity, has emerged as the therapeutic target of disease-modifying therapy for multiple sclerosis (MS). However, recent studies have revealed that NEDA-3 might not be sufficient to prevent cognitive deterioration and predict long-term disability. In addition to NEDA-3, brain atrophy has recently been recognized as a pivotal biomarker that is closely associated to disability in patients with MS...
July 4, 2018: Neurological Sciences
https://www.readbyqxmd.com/read/29948245/two-year-real-life-efficacy-tolerability-and-safety-of-dimethyl-fumarate-in-an-italian-multicentre-study
#6
Giulia Mallucci, P Annovazzi, S Miante, V Torri-Clerici, M Matta, S La Gioia, R Cavarretta, V Mantero, G Costantini, V D'Ambrosio, M Zaffaroni, A Ghezzi, P Perini, S Rossi, A Bertolotto, M R Rottoli, M Rovaris, R Balgera, P Cavalla, C Montomoli, R Bergamaschi
BACKGROUND: Dimethyl-fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting multiple sclerosis (MS) in randomized clinical trials. OBJECTIVES: To track and evaluate post-market DMF profile in real-world setting. MATERIALS AND METHODS: Patients receiving DMF referred to Italian MS centres were enrolled and prospectively followed, collecting demographic clinical and radiological data. RESULTS: Among the 735 included patients, 45...
August 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29875218/fingolimod-vs-dimethyl-fumarate-in-multiple-sclerosis-a-real-world-propensity-score-matched-study
#7
Luca Prosperini, Matteo Lucchini, Shalom Haggiag, Paolo Bellantonio, Assunta Bianco, Maria Chiara Buscarinu, Fabio Buttari, Diego Centonze, Antonio Cortese, Laura De Giglio, Roberta Fantozzi, Elisabetta Ferraro, Arianna Fornasiero, Ada Francia, Simonetta Galgani, Claudio Gasperini, Girolama Alessandra Marfia, Enrico Millefiorini, Viviana Nociti, Simona Pontecorvo, Carlo Pozzilli, Serena Ruggieri, Marco Salvetti, Eleonora Sgarlata, Massimiliano Mirabella
OBJECTIVE: To directly compare fingolimod (FNG) and dimethyl fumarate (DMF) on no evident disease activity (NEDA) status in patients with relapsing-remitting multiple sclerosis (RRMS) from 7 multiple sclerosis outpatient clinics in Central Italy. METHODS: We analyzed data of patients with RRMS who started an oral agent, namely DMF or FNG, either as first treatment (naives) or after switching from self-injectable drugs (switchers). We performed a propensity score (PS)-based nearest-neighbor matching within a caliper of 0...
July 10, 2018: Neurology
https://www.readbyqxmd.com/read/29870645/-alemtuzumab-therapy-2017
#8
REVIEW
Tamás Biernacki, Krisztina Bencsik, Dániel Sandi, László Vécsei
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system comprising of inflammation, demyelinisation and neurodegeneration. The natural history of MS is heterogenous. Owing to the vast range and severity of the symptoms MS can cause the effect of the disease on one's cognitive and physical status is unpredictable. According to the new, phenotype based classification two subgroups can be distinguished; relapsing-remitting (RR) and progressive MS. Relapsing-remitting MS can be further divided into active and inactive disease...
November 30, 2017: Ideggyógyászati Szemle
https://www.readbyqxmd.com/read/29870642/-is-second-line-immunomodulatory-treatment-effective-in-multiple-sclerosis
#9
Lilla Rácz, Ervin Berényi, Péter Barsi, Dávid Bernáth, Tünde Csépány
Background and purpose: Natalizumab is the first evidence based monoclonal antibody, which was launched for treatment in relapsing remitting multiple sclerosis in Hungary in 2010. Standardized follow-up is required to use it. Methods: Our aim was to evaluate the efficacy and to monitor the safety of natalizumab treatment by using an electronic database established for MS registry. Clinical activity was measured by annual relapse rates, functional status of patients measured by EDSS and MFSC...
July 30, 2017: Ideggyógyászati Szemle
https://www.readbyqxmd.com/read/29861258/responsiveness-of-postural-performance-measures-following-balance-rehabilitation-in-multiple-sclerosis-patients
#10
Hossein Negahban, Saeideh Monjezi, Mohammad Mehravar, Neda Mostafaee, Ali Shoeibi
INTRODUCTION: Evaluating responsiveness has an important role in design and interpretation of the interventional studies. The aim was to estimate the responsiveness and minimally important difference (MID) of postural performance measures following balance rehabilitation in patients with Multiple Sclerosis (MS, n = 38). METHODS: Postural measures were evaluated at baseline and after 4 weeks intervention. Laboratory-based measures were center of pressure parameters...
April 2018: Journal of Bodywork and Movement Therapies
https://www.readbyqxmd.com/read/29770137/gut-microbiota-confers-resistance-of-albino-oxford-rats-to-the-induction-of-experimental-autoimmune-encephalomyelitis
#11
Suzana Stanisavljević, Miroslav Dinić, Bojan Jevtić, Neda Đedović, Miljana Momčilović, Jelena Đokić, Nataša Golić, Marija Mostarica Stojković, Đorđe Miljković
Albino Oxford (AO) rats are extremely resistant to induction of experimental autoimmune encephalomyelitis (EAE). EAE is an animal model of multiple sclerosis, a chronic inflammatory disease of the central nervous system (CNS), with established autoimmune pathogenesis. The autoimmune response against the antigens of the CNS is initiated in the peripheral lymphoid tissues after immunization of AO rats with CNS antigens. Subsequently, limited infiltration of the CNS occurs, yet without clinical sequels. It has recently become increasingly appreciated that gut-associated lymphoid tissues (GALT) and gut microbiota play an important role in regulation and propagation of encephalitogenic immune response...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29761737/predictive-validity-of-neda-in-the-16-and-21-year-follow-up-from-the-pivotal-trial-of-interferon-beta-1b
#12
Douglas S Goodin, Anthony T Reder, Anthony L Traboulsee, David Kb Li, Dawn Langdon, Gary Cutter, Stuart Cook, Timothy O'Donnell, Marcelo Kremenchutzky, Joel Oger, Ralf Koelbach, Christoph Pohl, Eva-Maria Wicklein
BACKGROUND: Long-term follow-up from the randomized trial of interferon beta-1b (IFNB-1b) permitted the assessment of different definitions of no evidence of disease activity (NEDA) for predicting long-term outcome in multiple sclerosis (MS). OBJECTIVE: To examine the predictive validity of different NEDA definitions. METHODS: Predictive validity for negative disability outcomes (NDOs) at 16 years and survival at 21 years post-randomization were assessed...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29754703/progression-of-a-series-of-patients-with-relapsing-remitting-multiple-sclerosis-treated-for-7-years-with-natalizumab-using-the-no-evidence-of-disease-activity-parameter
#13
A Pato Pato, E Costa Arpín, A Rodríguez Regal, I Rodríguez Constenla, I Cimas Hernando, I Muñoz Pousa, L Naya Ríos, J R Lorenzo González, M C Amigo Jorrín, J M Prieto González
INTRODUCTION: The safety and effectiveness of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in clinical trials. However, due to the limitations of these trials, it is important to know how the condition behaves under long-term clinical practice conditions. OBJECTIVE: To determine the long-term effectiveness of natalizumab in patients with RRMS by means of annual evaluation of the "no evidence of disease activity" (NEDA) parameter, which includes number of relapses, disability (measured with the Expanded Disability Status Scale), and brain MRI parameters...
May 10, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29736227/molecular-mechanisms-of-omega-3-fatty-acids-in-the-migraine-headache
#14
REVIEW
Neda Soveyd, Mina Abdolahi, Sama Bitarafan, Abbas Tafakhori, Payam Sarraf, Mansoureh Togha, Ali Asghar Okhovat, Mahsa Hatami, Mohsen Sedighiyan, Mahmoud Djalali, Niyaz Mohammadzadeh Honarvar
Migraine is a common chronic inflammatory neurological disease with the progressive and episodic course. Much evidence have shown a role of inflammation in the pathogenesis of migraine. Omega-3 fatty acids are an important components of cell membranes phospholipids. The intake of these fatty acids is related to decrease concentration of C-reactive protein (CRP), proinflammatory eicosanoids, cytokines, chemokines and other inflammation biomarkers. Many of clinical trials have shown the beneficial effect of dietary supplementation with omega-3 fatty acids in inflammatory and autoimmune diseases in human, including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), multiple sclerosis (MS) and migraine headaches...
October 7, 2017: Iranian Journal of Neurology
https://www.readbyqxmd.com/read/29710121/association-of-retinal-ganglion-cell-layer-thickness-with-future-disease-activity-in-patients-with-clinically-isolated-syndrome
#15
Hanna G Zimmermann, Benjamin Knier, Timm Oberwahrenbrock, Janina Behrens, Catherina Pfuhl, Lilian Aly, Miriam Kaminski, Muna-Miriam Hoshi, Svenja Specovius, René M Giess, Michael Scheel, Mark Mühlau, Judith Bellmann-Strobl, Klemens Ruprecht, Bernhard Hemmer, Thomas Korn, Friedemann Paul, Alexander U Brandt
Importance: Clinically isolated syndrome (CIS) describes a first clinical incident suggestive of multiple sclerosis (MS). Identifying patients with CIS who have a high risk of future disease activity and subsequent MS diagnosis is crucial for patient monitoring and the initiation of disease-modifying therapy. Objective: To investigate the association of retinal optical coherence tomography (OCT) results with future disease activity in patients with CIS. Design, Setting, and Participants: This prospective, longitudinal cohort study took place between January 2011 and May 2017 at 2 German tertiary referral centers...
April 23, 2018: JAMA Neurology
https://www.readbyqxmd.com/read/29687559/-no-evidence-of-disease-activity-is-it-an-appropriate-surrogate-in-multiple-sclerosis
#16
REVIEW
H Hegen, G Bsteh, T Berger
The increasing number of disease-modifying treatments available for multiple sclerosis has broadened treatment options for patients, but also challenges clinicians to select the best therapy for each individual at the appropriate stage of the disease. Early prediction of treatment response still remains one of the main difficulties in the management of multiple sclerosis patients. The concept of 'no evidence of disease activity' (NEDA) has been proposed as a surrogate for treatment response based on the absence of relapses, disability progression and radiological activity...
April 24, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29679749/matching-adjusted-comparisons-demonstrate-better-clinical-outcomes-with-sc-peginterferon-beta-1a-every-two-weeks-than-with-sc-interferon-beta-1a-three-times-per-week
#17
Patricia K Coyle, Shulian Shang, Zhen Xiao, Qunming Dong, Carmen Castrillo-Viguera
BACKGROUND: Subcutaneous (SC) peginterferon beta-1a and SC interferon beta-1a (IFN beta-1a) have demonstrated efficacy in treating relapsing-remitting multiple sclerosis (RRMS) but have never been compared in direct head-to-head clinical trials, the gold-standard comparison. A well-balanced matching-adjusted comparison of weighted individual patient data on SC peginterferon beta-1a, and aggregate data from published phase 3 clinical trials of SC IFN beta-1a, was conducted to provide additional information on the comparative efficacy of these two agents...
May 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29652301/-the-results-of-an-open-comparative-retrospective-trial-of-the-course-of-multiple-sclerosis-during-treatment-with-infibeta-and-other-interferon-beta-bioanalogues-and-glatiramer-acetate
#18
F A Khabirov, T I Khaybullin, E V Granatov, S R Shakirzianova, N N Babicheva, O S Kochergina, E F Rakhmatullina, G M Akhmedova, L A Averyanova, M A Yakupov, Zh F Sabirov
AIM: To evaluate the efficacy and safety of the interferon beta-1b bioanalogue 'infibeta' in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. MATERIAL AND METHODS: The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29648900/no-evidence-of-disease-activity-in-patients-receiving-fingolimod-at-private-or-academic-centers-in-clinical-practice-a-retrospective-analysis-of-the-multiple-sclerosis-clinical-and-magnetic-resonance-imaging-outcomes-in-the-usa-ms-mrius-study
#19
Robert Zivadinov, Nasreen Khan, Jonathan R Korn, Ellen Lathi, Jason Silversteen, Jonathan Calkwood, Scott Kolodny, Diego Silva, Jennie Medin, Bianca Weinstock-Guttman
OBJECTIVE: The impact of multiple sclerosis (MS) center type on outcomes has not been investigated. This study aimed to evaluate baseline characteristics and clinical and magnetic resonance imaging (MRI) outcomes in patients with MS receiving fingolimod over 16 months' follow-up at private or academic centers in the USA. METHODS: Clinical and MRI data collected in clinical practice from patients initiating fingolimod were stratified by center type and retrospectively analyzed...
August 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29604233/permeability-of-the-blood-brain-barrier-predicts-no-evidence-of-disease-activity-at-2-years-after-natalizumab-or-fingolimod-treatment-in-relapsing-remitting-multiple-sclerosis
#20
Stig P Cramer, Helle J Simonsen, Aravinthan Varatharaj, Ian Galea, Jette L Frederiksen, Henrik B W Larsson
OBJECTIVE: To investigate whether blood-brain barrier (BBB) permeability, as measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), can provide early detection of suboptimal treatment response in relapsing-remitting multiple sclerosis (RRMS). METHODS: Thirty-five RRMS patients starting on fingolimod or natalizumab, drugs with a common effect of decreasing lymphocyte influx into the central nervous system, were scanned with DCE-MRI at 3T prior to treatment and at 3 and 6 months posttreatment...
May 2018: Annals of Neurology
keyword
keyword
158178
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"